Navigation Links
Rigel to Present New Research Programs at AACR Meeting

Focus on Rigel's Extensive Oncology Portfolio

SOUTH SAN FRANCISCO, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced the presentation of four research projects aimed at identifying small molecule inhibitors of select kinases as potential therapeutics for certain types of cancers and other disorders. Rigel scientists will give the presentations during poster sessions from April 16th to 18th (see list below) at the upcoming meeting of the American Association for Cancer Research in Los Angeles, California.

"We believe that Rigel's participation in this AACR meeting is an acknowledgment of the depth and breadth of our oncology R&D portfolio," said Donald G. Payan, M.D., executive vice president and chief scientific officer of Rigel. "We have established Rigel as a productive company in the discovery of oncology kinase products and believe that Rigel is well-positioned to take the lead in the next generation of oncology targets -- ligases," he added. Additional information regarding Rigel's oncology pipeline and ubiquitin ligase research can be found at http://www.rigel.com.

One of the presentations is entitled, "Small Molecule Inhibitors of the Axl Receptor Tyrosine Kinase as Therapeutics for Angiogenesis and Tumor Growth". Rigel's scientists have found that Axl signaling controls processes vital for both neovascularization and tumorigenesis in endothelial (smooth muscle) cells. Rigel has subsequently screened for and identified compounds that could potentially inhibit Axl expression. Lead compounds from this program have shown positive results in animal models of oncology and other areas. In addition to developing a treatment for certain cancers, Rigel's scientists believe that their therapeutic candidates' ability to suppress angiogenesis may have a role in treating endometriosis, a painful, chronic
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Rigel Present New Research Programs AACR Meeting
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Medina ... as CEO and member of the Board of Directors ... of medical device development and commercialization experience, including over ... Mr. Engelson previously served as a Partner of the ... President and CEO of two Foundry start-ups. Mr. Engelson ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... Sept. 21, 2011 Reportlinker.com announces that a ... catalogue: Generic Drugs: The ... http://www.reportlinker.com/p0619264/Generic-Drugs-The-Global-Market-Focus-on-the-Americas.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... examination of the strategies employed by companies specializing ...
... SAN DIEGO, Sept. 20, 2011 Orexigen® Therapeutics, Inc. ... a recent meeting with senior officials in FDA,s Office ... detailing OND,s design requirements for a cardiovascular outcomes trial ... Letter (CRL) received in January 2011. Orexigen believes that ...
Cached Medicine Technology:Generic Drugs: The Global Market: Focus on the Americas 2Generic Drugs: The Global Market: Focus on the Americas 3Generic Drugs: The Global Market: Focus on the Americas 4Generic Drugs: The Global Market: Focus on the Americas 5Generic Drugs: The Global Market: Focus on the Americas 6Generic Drugs: The Global Market: Focus on the Americas 7Generic Drugs: The Global Market: Focus on the Americas 8Generic Drugs: The Global Market: Focus on the Americas 9Generic Drugs: The Global Market: Focus on the Americas 10Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Monitoring For Drug Abuse Trends , Outbreaks (8/20), the National ... attempt to monitor drug abuse trends by turning to social ... drug abuse trends, it is also working with the University ... National Drug Early Warning System, which will be funded by ...
(Date:8/29/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Glass microfiber including its ... explores global and China’s top manufacturers of Glass ... and market share etc. , The report further ...
(Date:8/29/2014)... August 29, 2014 Dr. Parsa Mohebi M.D. ... of hair loss achieve great results in hair transplantation. ... Hair Transplant , an FUE method that harvests facial hair ... This method lets patients whose hair loss classification is 5 ... Transplant is a great alternative for those advanced hair loss ...
(Date:8/29/2014)... -- Astronauts may be at heightened risk of ... systems, a new study suggests. That could be ... the moon and Mars undertaken in the future, because ... be dangerous, NASA researchers say. They found that ... International Space Station crew members remains relatively unchanged during ...
(Date:8/29/2014)... 2014 Healthpointe Medical Group, one ... medical center from LAXMed. The medical center is less than ... miles west of the 405 freeway. , The LAX ... new LAX center is located at: 8610 S. Sepulveda Blvd., ... Healthpointe LAX office will provide the same comprehensive ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... Mayo Clinic review of patients responses to a drug ... general surgery questions a U.S. Food and Drug Administration ... appears in the current issue of the journal Anesthesiology. ... 2001 over concerns that the drug contributed to potentially ...
... This Decade ... OAKLAND, Calif., Sept. 28 Registered nurses at up to 16,Northern ... a major strike in October that could involve up to 5,500 ... Group in Yuba City and Marysville. Strike notices are being ...
... Center at Jefferson in Philadelphia have discovered new molecular ... breast cancer. They have found that prolactin, a pituitary ... initiates a new signaling pathway that may regulate the ... The work, which appears this month in the journal ...
... of William V. Corr, Executive Director, Campaign for,Tobacco-Free ... is a,statement of William V. Corr, Executive Director, ... will fall further behind in protecting,workers and the ... as two,more states - neighboring Maryland and Minnesota ...
... Insurance,Holdings, Inc. ("EIHI") (Nasdaq: EIHI ) announced ... Insurance Group ("EAIG") in the new position of,Regional ... an,indirect wholly-owned subsidiary of EIHI. EAIG entered ... licenses to underwrite in North Carolina, Virginia,Georgia and ...
... Cross,announces it has signed new three-year contracts with ... part of Catholic Health East health care,system, effective ... includes Mercy Fitzgerald Hospital, Mercy,Hospital of Philadelphia, Mercy ... Hospital, as well as Mercy Home Health and ...
Cached Medicine News:Health News:Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary 2Health News:RNs to Announce October Strike of 5,500 Nurses 2Health News:Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer 2Health News:Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit 2Health News:Eastern Alliance Insurance Group Appoints Cox Regional Marketing Director for Southeast 2Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 2Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 3
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: